| 000 | 01704 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250518080244.0 | ||
| 264 | 0 | _c20201112 | |
| 008 | 202011s 0 0 eng d | ||
| 022 | _a1432-0843 | ||
| 024 | 7 |
_a10.1007/s00280-019-04014-x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLiu, Ya-Nan | |
| 245 | 0 | 0 |
_aA randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects. _h[electronic resource] |
| 260 |
_bCancer chemotherapy and pharmacology _c03 2020 |
||
| 300 |
_a555-562 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAdministration, Intravenous _xmethods |
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Immunological _xpharmacokinetics |
| 650 | 0 | 4 | _aArea Under Curve |
| 650 | 0 | 4 |
_aBevacizumab _xpharmacokinetics |
| 650 | 0 | 4 |
_aBiosimilar Pharmaceuticals _xpharmacokinetics |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aHealthy Volunteers |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aTherapeutic Equivalency |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aHuang, Jie | |
| 700 | 1 | _aGuo, Can | |
| 700 | 1 | _aYang, Shuang | |
| 700 | 1 | _aYe, Ling | |
| 700 | 1 | _aWu, Shu-Ting | |
| 700 | 1 | _aZhang, Xing-Fei | |
| 700 | 1 | _aYang, Xiao-Yan | |
| 700 | 1 | _aHan, Cui-Cui | |
| 700 | 1 | _aPei, Qi | |
| 700 | 1 | _aHuang, Lu | |
| 700 | 1 | _aHe, Qing-Nan | |
| 700 | 1 | _aYang, Guo-Ping | |
| 773 | 0 |
_tCancer chemotherapy and pharmacology _gvol. 85 _gno. 3 _gp. 555-562 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00280-019-04014-x _zAvailable from publisher's website |
| 999 |
_c30489527 _d30489527 |
||